Changchun High-tech: Subsidiary GenSci134 injection obtains approval for registration and clinical trial of domestically produced drugs.

Changchun High-tech announced that its subsidiary, JinSai Pharmaceutical GenSci 134 injection, has received approval from the National Medical Products Administration for domestic drug registration clinical trials, intended for the treatment of idiopathic short stature. The product has been approved for clinical trials for adult growth hormone deficiency and has also received approval for domestic drug registration clinical trials for children with slow growth. If the clinical trials proceed smoothly, it will benefit the company in expanding its business structure and optimizing its product structure. Pharmaceutical products have the characteristics of high technology, high risk, and high added value. The early research and development of drugs and the long and multi-stage process from formulation to production involve uncertainties.